Thousands of eye care products sold nationwide are being recalled: See the list of impacted items
Be wary of what you put in your peepers: Nearly 76,000 cases of eye care products have been voluntarily recalled by their manufacturer following an audit by the U.S. Food and Drug Administration.
BRS Analytical Service, LLC, is voluntarily recalling several of its eye drop products, according to a notice from pharmaceutical distributor AvKARE. While no specific health issues have been reported, the recall was prompted by 'manufacturing CGMP deviations' — meaning the products may not meet FDA quality standards. It's unclear whether these deviations pose a risk to users, so the company is recalling the products as a precaution.
The affected products include artificial tears and other lubricating eye solutions and were first shipped between May 26, 2023, and April 21, 2025. They have expiration dates that range from April 2025 to March 2027 — meaning it's possible these items are still being used by customers.
You can find specific information about what products are recalled on the FDA's website. Below are the products that are recalled:
Artificial Tears Ophthalmic Solution
Drug Code: 50268-043-15
13,872 cases recalled
Carboxymethylcellulose Sodium Ophthalmic Solution 0.5%
Drug Code: 50268-066-15
1,610 cases recalled
Carboxymethylcellulose Sodium Ophthalmic Solution 0.5%
Drug Code: 50268-068-15
32,876 cases recalled
Lubricant Eye Drops Solution (Polyethylene Glycol 400 / Propylene Glycol)
Drug Code: 50268-126-15
13,104 cases recalled
Polyvinyl Alcohol Ophthalmic Solution 1.4%
Drug Code: 50268-678-15
14,333 cases recalled
If you find that you have one of these products, stop using it immediately. Consumers who want a refund can fill out a recall form and send it to AvKARE by fax or email, after which they'll receive instructions to return the product and get a full refund, including shipping.
This is not the first time in recent years that certain eye products have been the subject of scrutiny by the FDA. In October 2023, the FDA warned consumers about 26 over-the-counter eye care products, including eyedrops available at stores like CVS and Target, which came with the 'potential risk of eye infections that could result in partial vision loss or blindness.' At the time, the FDA discovered that the manufacturing facility had poor sanitation practices and that the products tested positive for bacteria, proving they weren't sterile as advertised.
And in September 2023, the FDA issued warning letters to eight companies for illegally marketing unapproved eye products that claim to treat conditions like pink eye, cataracts and glaucoma, some of which had sterility issues and/or contained silver, which can cause long-term health issues. The news came one month after the FDA warned consumers not to use Dr. Berne's and LightEyez MSM eye drops due to contamination risks and the use of an unapproved ingredient.
There was also an earlier wave of eye drop recalls in 2023, including one linked to EzriCare Artificial Tears that caused infections in dozens of people, resulting in hospitalizations, vision loss and at least one death, according to the FDA.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
17 minutes ago
- Associated Press
Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Jun 6, 2025-- Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. Patients treated with sibeprenlimab achieved a 51.2% (P<0.0001) reduction in proteinuria (as measured by 24-hour uPCR [urine protein-to-creatinine ratio]) at nine months of treatment when compared to placebo 1. The data were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria. The study, the largest Phase 3 IgAN trial conducted to date, also showed the safety profile of sibeprenlimab was favorable and consistent with previously reported data 1. Specifically, 76.3% of patients treated with sibeprenlimab experienced any Treatment Emergent Adverse Event (TEAE) versus 84.5% in the placebo group. 1 Patients who experienced a serious TEAE were 3.9% treated with sibeprenlimab compared to 5.4% treated with placebo. Sibeprenlimab received Priority Review designation from the FDA last month following its BLA filing in March. Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated regulatory approvals 2. Sibeprenlimab is an investigational monoclonal antibody that selectively inhibits the activity of APRIL (A PRoliferation-Inducing Ligand) in adults with IgAN. APRIL plays a key role in the 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic Gd-IgA1 and immune complex formation 3,4,5,6. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels 1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation 7. Sibeprenlimab is administered in a single-dose prefilled syringe for subcutaneous injection every four weeks intended for self-administration or administration by caregiver, providing patients the option of convenience at home. 'We are confident about the potential of sibeprenlimab and are grateful to the patients who are helping to further the science by participating in these important trials,' said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc. 'Proteinuria control is an important independent predictor for long-term prognosis, and this interim data reinforces our belief that selectively targeting APRIL has the potential to be an effective and safe approach for this progressive and irreversible kidney disease.' The VISIONARY study continues in a blinded manner to evaluate the change in kidney function over 24 months as measured by estimated glomerular filtration rate (eGFR) and is expected to be completed in early 2026. Further prespecified and exploratory analyses of the data will be conducted to determine the full potential of sibeprenlimab for the treatment of IgAN 1. 'The VISIONARY Phase 3 interim analysis shows a robust proteinuria reduction of 51.2% in the group treated with sibeprenlimab relative to placebo. These results affirm our belief in the efficacy of sibeprenlimab in the largest Phase 3 IgAN trial to date. The study enrolled a diverse patient population reflective of the disease epidemiology,' said Dr. Dana Rizk, professor of medicine in the division of nephrology at the University of Alabama at Birmingham. 'The safety data emerging from VISIONARY is reassuring and adds to our existing knowledge about sibeprenlimab's safety profile from prior programs. This is very exciting news for patients and adds a therapeutic option with a novel mechanism of action potentially targeting the immunologic pathogenesis of IgAN.' About the VISIONARY Study The VISIONARY study is the largest IgAN trial to date, and is a multicenter, randomized, double-blind, placebo-controlled trial consisting of approximately 510 adult patients with IgAN who were receiving standard-of-care therapy (defined as maximally tolerated ACE inhibitor or ARB +/- SGLT2 inhibitor), designed to evaluate the efficacy and safety of sibeprenlimab 400 mg administered subcutaneously every four weeks, compared to placebo 1. The primary efficacy endpoint is to evaluate the change in 24-hour uPCR at 9 months compared with baseline. The secondary endpoint is to evaluate the annualized slope of eGFR estimated over ~24 months 1. About Sibeprenlimab Sibeprenlimab (formerly VIS649) was designed and engineered by Visterra, Inc., a wholly owned subsidiary of Otsuka. Pre-clinical and early-stage trials of sibeprenlimab were also conducted by Visterra. Sibeprenlimab is an investigational monoclonal antibody that selectively binds to and inhibits the activity of APRIL and plays a key role in the 4-hit process. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA1 levels 1. Lower levels of Gd-IgA1 in people with IgAN provide less substrate for immune complex formation 7. Decreased immune complex formation should result in diminished deposition in the kidney, and reduced proteinuria and kidney inflammation 8. By reducing the production of Gd-IgA1, sibeprenlimab may help slow kidney damage and progression toward ESKD 3,4,5,6. By inhibiting APRIL, sibeprenlimab may help address one of the IgAN-specific drivers for nephron loss. About IgAN and APRIL IgAN is a progressive, immune-mediated, chronic kidney disease that typically manifests in adults aged 20-40 years and leads to ESKD over the lifetime of most patients 9,10,11. IgAN is characterized by the accumulation of Gd-IgA1 complexes in the kidneys. IgAN can lead to progressive loss of kidney function and, eventually, ESKD, imposing a significant burden on patients 10. Despite supportive care, there is an unmet need for treatments that address the root causes of the condition. Continued research in the disease remains crucial to uncovering opportunities for advancement in our understanding and treatment of patients 5. APRIL, a cytokine in the tumor necrosis factor (TNF) family, is integral to the pathogenesis and progression of IgAN. It promotes the survival and class switching of B cells to produce IgA, particularly the pathogenic galactose-deficient IgA1 (Gd-IgA1) that forms immune complexes in the kidneys 5. About Otsuka Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a 'big venture' company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies' 2,250 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 35,340 people worldwide and had consolidated sales of approximately USD 14.7 billion in 2024. All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.'s global website is accessible at About Visterra Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases. Its proprietary Hierotope® platform enables the design and engineering of precision biologics-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting kidney diseases, immunologically-driven diseases and infectious diseases. Visterra is an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. For more information, visit References View source version on CONTACT: Contacts for MediaOtsuka in the Murphy Corporate Communications Otsuka America Pharmaceutical, Inc. [email protected]+1 609 249 7262Otsuka in JapanJeffrey Gilbert Leader, Pharmaceutical PR Otsuka Pharmaceutical Co., Ltd. [email protected]+81 3 6361 7379 KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC NEW JERSEY INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA CLINICAL TRIALS OTHER HEALTH SOURCE: Otsuka Pharmaceutical Co., Ltd. Copyright Business Wire 2025. PUB: 06/06/2025 06:00 AM/DISC: 06/06/2025 05:58 AM

Associated Press
an hour ago
- Associated Press
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine
IBN published this article, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 5, 2025 ( NEWMEDIAWIRE ) - NRx Pharmaceuticals (NASDAQ: NRXP), has submitted an Abbreviated New Drug Application (ANDA) to the FDA for NRX-100, its preservative-free intravenous ketamine formulation aimed at approved indications such as anesthesia and pain management. With the U.S. ketamine market valued at $750 million and global demand projected to reach $3.35 billion by 2034, the company is seeking priority review amid an ongoing national shortage. NRx also plans to petition the FDA to mandate preservative-free ketamine formulations, citing safety concerns over benzethonium chloride. This filing complements its broader strategy to expand ketamine's label to include treatment for suicidal depression, backed by clinical data from more than 1,000 patients. To view the full press release, visit About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to NRXP are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected] View the original release on
Yahoo
2 hours ago
- Yahoo
3D Printing Technology Revolutionizes Breast Implants Industry - A $4.6 Billion Market by 2030
Key players like Johnson & Johnson and Establishment Labs are driving innovation with FDA-approved products. Silicone implants lead the market due to their natural feel. North America dominates in market share, fueled by high awareness and cosmetic spending. Innovative trends like 3D printing are reshaping the industry. Breast Implants Market Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Breast Implants Market - Focused Insights 2025-2030" report has been added to Breast Implants Market was valued at USD 2.98 Billion in 2024, and is projected to reach USD 4.60 Billion by 2030, rising at a CAGR of 7.5%. The global breast implants market is set to grow due to the growing popularity of anatomical breast implants and generation-to-generation development in breast implants. KEY TAKEAWAYS By Product: The silicone breast implants segment holds the largest market share, as they are highly popular for offering a natural look and feel while maintaining shape even if ruptured. By Shape: The round shape segment shows the highest of 7.70%, as they are the most preferred breast implant shape category because they offer a fuller size across the breast area and limit the rotation of implants. By Surface: In 2024, the smooth surface segment accounted for the largest market share. Smooth surface breast implants are widely used for their natural feel and movement, enhancing effectiveness and reducing the need for repeat surgeries. By Application: The breast augmentation segment accounted for the largest market share. Breast augmentation is a top cosmetic surgery worldwide, with rising demand due to cosmetic and medical needs. By End-User: The cosmetology clinics segment holds the second largest market share of over 34%, driven by specialized, well-trained, well-experienced, and experienced plastic surgeons who regularly perform breast implant procedures in cosmetology clinics. By Geography: North America dominates the global breast implants market, with over 24% share. North America's breast implant market is growing steadily due to rising awareness, high beauty care spending, and interest in advanced procedures. BREAST IMPLANTS MARKET TRENDS & DRIVERS Rapid Development in Breast Implants with 3D Printing TechnologyThe breast implant industry is rapidly evolving with advancements in development and manufacturing technologies that create significant demand for breast implants. Of such one major development is the incorporation of 3D development technologies in the manufacturing and development of breast implants. It was started in the last decade when first-in-human clinical trials of 3D-printed breast implants (2019) were started in Germany, and now it is widespread across the global market. These 3D printing and development technologies offer the highest level of customization that attracts a significant consumer base. BellaSeno is one of the German companies that uses Evonik's Resomer polymer in its Senella breast implant (3D-printed) breast scaffold products. The polymer allows the scaffold to be absorbed in the body at a rate that matches the patient's Popularity of Anatomical Breast ImplantsRound shape breast implants are considered the gold standard for breast augmentation and reconstruction; however, in recent years, the development of anatomical implants has become an exciting trend in the industry. It involves the application of custom-molded implants that are designed and developed to mimic the shape and give a natural feel. Where anatomical breast implants become an ideal choice for women who are seeking to achieve a balanced look with a natural shape. Anatomical breast implants also known as tear-drop breast implants now commonly referred to as contour profile or shaped breast implants. These implants are filled with gel which gives a more natural feel and comfort making them the most popular choice among youngsters. These increasing applications in breast enlargement to breast implant exchange become popular for patients undergoing revision breast surgery, such as those patients who demand poly implant prostheses (PIP) implant Development in Breast ImplantsThe world of breast implants has witnessed significant and continued developments. Fourth and fifth-generation breast implants revolutionized the breast implant industry. In these generations, significant changes were noticed related to silicone gel cohesivity. In 4th and 5th generation breast implants, the shell of implants was further strengthened, and cohesive versions of silicone gel were used to significantly minimize complications related to gel leakage. In 5th-generation implants, they come up with highly form-stable gel that characterizes gummy bear implants. In addition, Establishment Lab - one of the key companies in the market came up with 6th generation breast implant. The company focused on a patient-centric approach in incorporating and developing revolutionary techniques in its Motiva product to enhance both safety and aesthetic outcomes- MOTIVA IMPLANTS. It is a first-of-their-kind feature that significantly revolutionizes the Volume of Breast Enhancement ProceduresWorldwide, with the widespread of cosmetology and medical aesthetic procedures, breast augmentation procedures become the second leading surgical cosmetic procedure. According to the International Society of Aesthetic Plastic Surgery (ISAPS) report 2024, more than 1.89 million breast augmentation procedures performed across the world contribute to significant demand for breast implants. Furthermore, the ISAPS article 2024 revealed that more than 4.1 million breast procedures were reported across the world. Of these, over 1.89 million surgical breast augmentation, around 903,266 breast lifts, approx. 686,000 breast reduction, and 335,939 breast implant removal procedures reported across the world. It indicates that the demand for breast surgeries is significantly high across the BREAST IMPLANTS MARKET SEGMENT INSIGHTS Key Market Segments Product: Silicone breast implants control the largest share, emphasizing their popularity for a natural appearance. Shape: Round shapes lead with a 7.70% growth rate, preferred for full-size enhancement and reduced implant rotation. Surface: Smooth surface implants dominate due to their natural feel and reduced need for replacements. Application: Breast augmentation claims the largest application share, fueled by rising cosmetic and medical demands. Geography: North America holds a dominant market share, driven by elevated awareness and advanced procedural needs. COMPETITIVE LANDSCAPEThe global breast implants market report consists of exclusive data on 13 vendors. AbbVie, Establishment Labs, Johnson & Johnson (MENTOR), GC Aesthetics, POLYTECH Health & Aesthetics, and Tiger Biosciences are among the leading companies holding a significant market share in the global breast implants market. These vendors offer high-quality and advanced breast implant solutions that meet customer demands and comply with regulatory standards. Major players are continuously enhancing the efficiency of their products and strengthening their market positions. They benefit from strong brand recognition and a broad geographical presence across global markets. Furthermore, the adoption of various strategic initiatives, such as product launches and the development of new products with advanced technologies and materials, has intensified market competition. By focusing on innovation and expanding their capabilities, these companies have successfully increased their revenue share and maintained a competitive edge in the breast implants Strategic Approaches to Strengthen Sales Ratios In 2025, Establishment Labs developed and launched Preserve, a minimally invasive breast tissue preserving technology for breast augmentation, mastopexy augmentation, and revision augmentation procedures. In 2024, the company established a manufacturing and corporate office in Costa Rica to increase the manufacturing capacity of breast implants and other products, which will create revenue growth opportunities. In 2024, Stratasys and CollPlant announced a collaboration to conduct a pre-clinical study for advanced and unique regenerative commercial-sized breast implants. With this collaboration, the companies reported that technology innovations will address around a $3 billion market opportunity in the future. In 2023, AbbVis' Allergen Aesthetics launched the Natrelle Campaign, which will promote and create awareness about the company's breast implant solutions with a higher level of customization. In 2023, Establishment Labs Holding announced the launch of Mia Femtech, a company that offers minimally invasive breast augmentation procedures in Japan to establish a new beginning in breast aesthetics. This expansion will deliver significant brand awareness about its breast implant solution in the Asian market. Key Vendors AbbVie Establishment Labs Johnson & Johnson (MENTOR) GC Aesthetics POLYTECH Health & Aesthetics Tiger Biosciences Other Prominent Vendors Bimini Health Tech Hans Biomed Guangzhou Wanhe Plastic Material Co., Ltd G.A.L.S. Private Limited Laboratoires Arion Sebbin Silimed Key Attributes: Report Attribute Details No. of Pages 136 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.98 Billion Forecasted Market Value (USD) by 2030 $4.6 Billion Compound Annual Growth Rate 7.5% Regions Covered Global Key Topics Covered: Chapter 1: Scope & Coverage: Breast Implants Market Overview Chapter 2: Breast Implants Market Premium Insights Key Highlights Regional Insights Chapter 3: Breast Implants Market Prospects & Opportunities Chapter 4: Breast Implants Market Industry Overview Projected Revenue of Breast Implants Market (2021-2030; $ Billions) Chapter 5: Breast Implants Market Segmentation Data Projected Revenue by Product (2021-2030; $ Billions) Silicone Saline Projected Revenue by Shape (2021-2030; $ Billions) Round Anatomical Projected Revenue by Surface (2021-2030; $ Billions) Smooth Textured Projected Revenue by Application (2021-2030; $ Billions) Breast Augmentation Breast Reconstruction Projected Revenue by End-user (2021-2030; $ Billions) Hospital Cosmetology Clinics Other End-user Chapter 6: Key Regions Overview Projected Revenue of Breast Implants Market (2021-2030; $ Billions) North America Europe Latin America APAC Middle East & Africa Chapter 7: Competitive Landscape of Breast Implants Market Competitive Landscape Key Vendor Profiles Other Prominent Vendors Key Strategic Recommendations For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Breast Implants Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio